StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
COLL$31.78-5.44%
Fair $31.78+0.0%

COLL

Collegium Pharmaceutical, Inc.

Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS

$31.78

-1.83 (-5.44%)

Fairly Valued+0.0%Fair Value $31.78Fund rank 32/100 · Data gapFallback financials|
SA 44/C
F-Score: 5/9
High Debt

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $274.3M · quality 58.7/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 87/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 13Warnings: 1unknown: 13
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 2.70, above the 2.0 threshold
Thesis & Journal · COLLLocal privado en este navegador · Collegium Pharmaceutical, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.0B

P/E

15.4x

↓

EV/EBITDA

4.6x

↓

ROE

20.8%

↑

Gross Margin

59.3%

↑

Debt/Equity

2.70

↑
52-Week Range$32
$29$51

TradingView lightweight chart

COLL price, volumen y niveles de valoración

Último $31.78Periodo +158.6%
Fair value: $31.78

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2013–2025 · 12 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

42.0%

FCF / Net income

5.21x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $780.6M · net income $62.9M · FCF $327.6M

2013-FY → 2025-FY

Gross margin

59.3%— pts

Operating margin

22.9%— pts

Net margin

8.1%— pts

FCF margin

42.0%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Income Statement
Revenue$780.6M$780.6M$631.4M$566.8M$463.9M$276.9M$310.0M$296.7M$280.4M$28.5M$1.7M———
Net Income$62.9M$62.9M$69.2M$48.2M$-25.0M$71.5M$26.8M$-22.7M$-39.1M$-74.9M$-94.2M$-27.3M$-17.9M$-16.2M
EBITDA$401.0M$401.0M$341.7M$308.3M$173.3M——$-23.0M$-19.6M$-74.9M$-93.4M$-26.7M$-17.5M—
EPS1.731.731.861.29-0.741.860.76-0.68-1.19—-3.88-1.48-22.72—
Gross Margin59.3%59.3%59.8%57.5%45.2%54.4%58.0%34.7%40.9%—————
Operating Margin22.9%22.9%26.4%29.5%7.2%6.4%18.1%-8.0%-7.4%-264.9%-5498.7%———
Net Margin8.1%8.1%11.0%8.5%-5.4%25.8%8.6%-7.7%-14.0%-262.9%-5504.1%———
Balance Sheet
Debt/Equity2.702.703.753.453.64——0.130.13—0.03———
Current Ratio1.711.71————————————
Cash Flow
Free Cash Flow$327.6M$327.6M$203.3M$274.3M$122.6M$101.6M$88.4M$21.3M$163.9M$-68.0M$-75.5M$-21.9M——
Returns
ROE20.8%20.8%30.2%24.6%-12.8%35.2%14.4%-26.0%-42.7%-71.9%-69.8%-32.0%20.1%23.7%
Valuation
P/E15.4315.4315.8725.04——————————
EV/EBITDA4.604.605.805.798.68—————————
P/B4.184.185.216.914.97—————————
Growth & Yield
Revenue Growth23.6%23.6%11.4%22.2%—-10.7%4.5%5.8%884.7%1564.3%————
EPS Growth-7.0%-7.0%44.2%274.3%—144.7%211.8%42.9%——-162.2%93.5%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

17.7%

exigente

EPS terminal req.

$2.82

Spread vs growth

-24.7%

5Y implied EPS CAGR

14.6%

razonable

EPS terminal req.

$3.41

Spread vs growth

-21.5%

10Y implied EPS CAGR

12.3%

razonable

EPS terminal req.

$5.50

Spread vs growth

-19.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +9.1%

Total return

+9.1%

Start / end P/E

15.7x → 18.4x

EPS bridge

1.86 → 1.73

Residual

-1.2%

EPS growth-7.0%
Multiple rerating+17.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-1.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.